Similar articles

• Treatment of renovascular disease and of renovascular hypertension.

  Bernini G, Pinto S, Arzilli F, Moretti A, Vignali C, Bartolozzi C, Salvetti A. Bernini G, et al. J Nephrol. 1998 Nov-Dec;11(6):311-7. J Nephrol. 1998. PMID: 10048497 Review.
• Captopril, an orally active angiotensin I converting enzyme inhibitor in the treatment of renovascular and essential hypertension.

  Holtzman E, Rosenthal T, Stern N, Knecht A, Yaron A. Holtzman E, et al. Isr J Med Sci. 1982 May;18(5):597-602. Isr J Med Sci. 1982. PMID: 6284678
• Volume and vasoconstriction in experimental renovascular hypertension.

  Freeman RH, Davis JO, Seymour AA. Freeman RH, et al. Fed Proc. 1982 Jun;41(8):2409-14. Fed Proc. 1982. PMID: 7044827
• New concepts of the renin system and of vasoconstriction-volume mechanisms. Diagnosis and treatment of renovascular and renal hypertensions.

  Vaughan EF Jr, Laragh JH. Vaughan EF Jr, et al. Urol Clin North Am. 1975 Jun;2(2):237-57. Urol Clin North Am. 1975. PMID: 1098253 Review.
• Role of neuropeptide Y in the development of two-kidney, one-clip renovascular hypertension in the rat.

  Shin LH, Dovgan PS, Nypaver TJ, Carretero OA, Beierwaltes WH. Shin LH, et al. J Vasc Surg. 2000 Nov;32(5):1015-21. doi: 10.1067/mva.2000.108642. J Vasc Surg. 2000. PMID: 11054234